Using lipid nanoparticles (LNPs), NMIN research leaders Drs. Pieter Cullis and Christian Kastrup, together with colleagues at The University of British Columbia (UBC), have developed a new tool that can inhibit the activity of a blood protein involved in thrombosis and a number of other afflictions. The protein in question,… Read More »NMIN researchers: A new nanomedicine treatment for thrombosis?
In a new review article published in Advanced Drug Delivery Reviews, NMIN researchers and colleagues discuss the use of state-of-the-art lipid nanoparticle (LNP) technology for therapeutic gene regulation in the liver. LNP technology enables the delivery of nucleic acids to treat liver diseases, addressing the root causes of these diseases… Read More »Lipid nanoparticle technology: poised to have a revolutionary impact
On March 31, 2020, NMIN’s Board of Directors approved a second round of research investment, supporting nine new projects—two within each of NMIN’s Research Themes (Targeted Drug Delivery, Gene Therapy, and Diagnostics), and three Strategic Initiatives. These new projects and initiatives, listed below by Research Theme, added 22 researchers and… Read More »Update: NMIN makes nine new research investments
NMIN Research Leader Dr. Shana Kelley discusses how new rapid diagnostic technologies could transform the way the COVID-19 pandemic is managed, in a webinar recorded on July 7, 2020. https://youtu.be/Zj4-N_CyuRg In the video, Dr. Kelley discusses innovative technologies being developed by researchers in her multidisciplinary PRiME group, including NMIN researcher… Read More »NMIN research leader discusses new diagnostic technology as key to “pandexit”
As of July 13, 2020, NMIN has a new Manager of Research and Partnerships: April O’Connell, BA, CHRP, CHRL. April brings eight years’ experience managing a multimillion-dollar research portfolio for AllerGen NCE. April was nationally recognized in 2019 for excellence in research management by the Canadian Association of Research Administrators… Read More »Meet April O’Connell, NMIN’s new Manager, Research & Partnerships
Two NMIN researchers based at the University of British Columbia (UBC) have been awarded CIHR funding to support projects addressing COVID19-related health challenges. NMIN’s Scientific Director, Dr. Pieter Cullis, was awarded $237,445 in support of his effort to develop an antibody therapy for COVID-19. The project, seed-funded by NMIN, will… Read More »NMIN researchers awarded CIHR funding for COVID-19 projects
The NanoMedicines Innovation Network (NMIN) is pleased to welcome the following new members to its Board of Directors (L to R above): Vanessa Grant, Partner, Norton Rose Fulbright Canada LLP Inès Holzbaur, Co-Founder & Managing Partner, AmorChem David Martin, Managing Director & Head of Equity Research, Bloom Burton Securities “We… Read More »NMIN welcomes three new Board members
NMIN research co-leader Dr. Christan Kastrup and his research team find that soil silicates play a key role in blood clotting Research led by Dr. Christian Kastrup and published in Blood Advances has found that soil silicates in wounds help activate a blood known as protein coagulation Factor XII. This… Read More »Soil stops bleeding: NMIN researcher
NMIN has granted Strategic Initiative funding to kick-start an effort to develop nanomedicines to fight COVID-19. NMIN’s Scientific Director Dr. Pieter Cullis leads this initiative, which is exploring the use of lipid nanoparticle (LNP) formulations of mRNA as therapeutics and vaccines for CVID-19. “In collaboration with industry partners, this project… Read More »NMIN seed-funds COVID-19 therapeutics project
In an insightful 42-minute interview, NMIN’s Scientific Director Dr. Pieter Cullis, a pioneer in liposomal gene and drug delivery, discusses his scientific career with a focus on his contributions to the evolution of gene therapy. https://www.youtube.com/watch?v=ERU-3b6YtUkThe interview was conducted on behalf of the Gene Delivery and Gene Editing focus group… Read More »The Ins & Outs of Gene Therapy Drug Development: an interview with NMIN’s Scientific Director